Program
Clopidogrel
Also written as “clopidogrel”, “clopidogrel (SR25990C)” and “Clopidogrel (SR25990)”.
Its studies are mostly in Coronary Artery Disease · Cardiovascular Diseases · Acute Coronary Syndrome · Heart Defects, Congenital · Diabetes Mellitus, Type 2, led by 17 companies.
Drug pageClopidogrel: every studyMany companies study it; this page follows only the 55 they lead. All 341 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 250 open or running | phase 4since Feb 23, 2006 | Dec 20, 2002 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 6, 2012 | Jan 6, 2012 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 1since Jun 4, 2010 | Jun 4, 2010 | none ahead |
| Bristol-Myers Squibbits history only | 30 open or running | phase 1since Jul 8, 2009 | Jul 8, 2009 | none ahead |
| Eli Lillyits history only | 30 open or running | phase 2since Jul 26, 2006 | Jul 26, 2006 | none ahead |
| Viatrisits history only | 30 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 2since Nov 13, 2014 | Nov 13, 2014 | none ahead |
| Les Laboratoires des Médicaments Stérilesits history only | 20 open or running | phase 4since Aug 25, 2011 | Aug 25, 2011 | none ahead |
| Merckits history only | 20 open or running | phase 1since Nov 10, 2009 | Nov 10, 2009 | none ahead |
| Accumetricsits history only | 10 open or running | no phasesince Mar 24, 2008 | Mar 24, 2008 | none ahead |
| Boston Scientificits history only | 10 open or running | phase 4since May 1, 2012 | May 1, 2012 | none ahead |
| Cordisits history only | 10 open or running | phase 4since Aug 6, 2009 | Aug 6, 2009 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 4since Apr 5, 2013 | Apr 5, 2013 | none ahead |
| Laboratoires Teriakits history only | 10 open or running | phase 4since Oct 14, 2017 | Oct 14, 2017 | none ahead |
| Novo Nordiskits history only | 10 open or running | phase 1since May 16, 2012 | May 16, 2012 | none ahead |
| Otsukaits history only | 10 open or running | phase 1since Sep 15, 2015 | Sep 15, 2015 | none ahead |
| Pharmtechnologyits history only | 10 open or running | phase 1since Jun 28, 2023 | Jun 28, 2023 | none ahead |
Also a collaborator on its studies: Bayer and Daiichi Sankyo.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 40 studies since Dec 20, 2002.
- Jan 9, 2012Phase 4 study in Cardiovascular DiseasesLes Laboratoires des Médicaments Stériles · NCT01509365 · 116 enrolled · Tunisia
- May 1, 2012Boston Scientific’s first study: phase 4 study in Coronary Artery DiseaseNew to Boston ScientificBoston Scientific · NCT01589978 · 2,681 enrolled · United States
- May 16, 2012Novo Nordisk’s first study: phase 1 study in HaemostasisNew to Novo NordiskNovo Nordisk · NCT01603342 · 18 enrolled · United States
- Jun 14, 20122 phase 1 studiesDr. Reddy's Laboratories · NCT01621763, NCT01621750
- Apr 5, 2013Hanmi Pharmaceutical’s first study: phase 4 study in Coronary Artery DiseaseNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01830491 · 162 enrolled
- Jul 4, 2014Phase 1 study in Bioequivalence, AUC, Cmax, PharmacokineticsAstraZeneca · NCT02185534 · 144 enrolled · Germany
- Nov 13, 2014Johnson & Johnson’s first study: phase 2 study in Acute Coronary SyndromeNew to Johnson & JohnsonJohnson & Johnson · NCT02293395 · 3,037 enrolled · United States, Argentina, Australia and more
- Apr 2, 2015Phase 1 study in ThrombosisBristol-Myers Squibb · NCT02439190 · 42 enrolled · United Kingdom
- Sep 15, 2015Otsuka’s first study: phase 1 study in HealthyNew to OtsukaOtsuka · NCT02554721 · 77 enrolled · Germany
- Oct 14, 2017Laboratoires Teriak’s first study: phase 4 study in Diabetes Mellitus, Type 2New to Laboratoires TeriakLaboratoires Teriak · NCT03329261 · 167 enrolled · Tunisia
- Jan 30, 2018Phase 1 study in HealthyViatris · NCT03430661 · 77 enrolled · United States
- Apr 6, 2018Phase 1 study in Healthy SubjectsJohnson & Johnson · NCT03496506 · 22 enrolled · Belgium
- Oct 4, 2018Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT03698513 · 113 enrolled · United States
- Jun 28, 2023Pharmtechnology’s first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT05934799 · 60 enrolled · Russian Federation
TargetBeta
“Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist”ChEMBL 37, by rule
Other programs on P2RY12
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ticagrelorrule | AstraZeneca | phase 4 | 47 |
| selatogrelrule | Viatris | phase 3 | 11 |
Studies
All 55 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05934799Bioequivalence · Russian Federation | 1 | Completed | Pharmtechnology | Jul 23, 2023 | 60 |
| NCT03698513Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Feb 19, 2019 | 113 |
| NCT03496506Healthy Subjects · Belgium | 1 | Completed | Johnson & Johnson | May 10, 2018 | 22 |
| NCT03430661Healthy · United States | 1 | Completed | Viatris | May 20, 2019 | 77 |
| NCT03329261Diabetes Mellitus, Type 2 · Tunisia | 4 | Completed | Laboratoires Teriak | Mar 24, 2019 | 167 |
| NCT02554721Healthy · Germany | 1 | Completed | Otsuka | Mar 30, 2018 | 77 |
| NCT02439190Thrombosis · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Mar 2016 | 42 |
| NCT02293395Acute Coronary Syndrome · United States, Argentina, Australia and more | 2 | Completed | Johnson & Johnson | Oct 14, 2016 | 3,037 |
| NCT02185534Bioequivalence, AUC, Cmax, Pharmacokinetics · Germany | 1 | Completed | AstraZeneca | Oct 2014 | 144 |
| NCT01830491Coronary Artery Disease | 4 | Completed | Hanmi Pharmaceutical | Aug 2009 | 162 |
| NCT01621763Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2008 | 68 |
| NCT01621750Fasting · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2008 | 68 |
| NCT01603342Haemostasis · United States | 1 | Completed | Novo Nordisk | Jan 2008 | 18 |
| NCT01589978Coronary Artery Disease · United States | 4 | Completed | Boston Scientific | Aug 2014 | 2,681 |
| NCT01512485Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Oct 2006 | 51 |
| NCT01509365Cardiovascular Diseases · Tunisia | 4 | Completed | Les Laboratoires des Médicaments Stériles | Feb 2015 | 116 |
| NCT01506713Fasting · Canada | 1 | Completed | Dr. Reddy's Laboratories | Sep 2006 | 53 |
| NCT01431495Coronary Disease · Tunisia | 4 | Completed | Les Laboratoires des Médicaments Stériles | Jun 2011 | 219 |
| NCT01263093Depressive Disorder, Major · United States | 1 | Completed | Eli Lilly | Mar 2011 | 47 |
| NCT01210339Cardiovascular Diseases · Sweden | 1 | Completed | AstraZeneca | Aug 2011 | 58 |
| NCT01147588Healthy · United States | 1 | Completed | AstraZeneca | May 2011 | 149 |
| NCT01129427Healthy · United States | 1 | Completed | Sanofi | Nov 2009 | 66 |
| NCT01129414Healthy · United States | 1 | Completed | Sanofi | Aug 2009 | 72 |
| NCT01129388Healthy · United States | 1 | Completed | Sanofi | May 2009 | 72 |
| NCT01129375Healthy · United States | 1 | Completed | Sanofi | May 2009 | 72 |
| NCT01129271Healthy · United States, France | 1 | Completed | Sanofi | Jun 2009 | 72 |
| NCT01129063Healthy · France | 1 | Completed | Sanofi | May 2009 | 32 |
| NCT01123824Healthy · Germany | 1 | Completed | Sanofi | Aug 2009 | 40 |
| NCT01115738Acute Coronary Syndrome · India | 2 | Completed | Eli Lilly | Nov 2011 | 282 |
| NCT01108588Healthy Volunteers | 1 | Completed | Merck | Aug 2010 | 15 |
| NCT01012219Hyperlipoproteinemia Type II | 1 | Completed | Merck | Mar 2010 | 36 |
| NCT00954707Coronary Artery Disease · United States | 4 | UNKNOWN | Cordis | Jan 2012 | 2,509 |
| NCT00935506Cardiovascular Diseases · United States | 1 | Completed | Bristol-Myers Squibb | Oct 2009 | 15 |
| NCT00862420Peripheral Arterial Disease · Japan | 3 | Completed | Sanofi | May 2011 | 431 |
| NCT00833703Heart Defects, Congenital · United States, Brazil, France and more | 3 | Completed | Sanofi | Jul 2010 | 49 |
| NCT00821834Angina, Stable · Japan | 3 | Completed | Sanofi | Aug 2010 | 1,003 |
| NCT00814268Stroke · Korea, Republic of | 4 | Completed | Sanofi | May 2012 | 358 |
| NCT00716924Thrombosis · Mexico | 3 | Completed | Sanofi | Feb 2006 | 155 |
| NCT00714961Acute Coronary Syndrome · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Jan 2005 | 3,491 |
| NCT00650169Healthy · United States | 1 | Completed | Viatris | Jan 2005 | 47 |
| NCT00648947Healthy · United States | 1 | Completed | Viatris | Dec 2004 | 46 |
| NCT00648453Peripheral Arterial Disease · Hungary | 4 | Completed | Sanofi | 39 | |
| NCT00645918Coronary Artery Disease · United States, Canada | – | Completed | Accumetrics | Oct 2010 | 2,800 |
| NCT00396877Heart Defects, Congenital · United States, Argentina, Belgium and more | 3 | Completed | Sanofi | Feb 2010 | 906 |
| NCT00386191Cerebral Infarction · Japan | 4 | Completed | Sanofi | Dec 2008 | 1,110 |
| NCT00360386Ischemia | 2 | Completed | Sanofi | Feb 2005 | 110 |
| NCT00357968Coronary Artery Disease · United States, France, Germany and more | 2 | Completed | Eli Lilly | Jun 2007 | 201 |
| NCT00335452Angina, Unstable · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Sep 2009 | 25,086 |
| NCT00325390Platelet Aggregation Inhibitors · Japan | 3 | Completed | Sanofi | 800 | |
| NCT00296803Metabolic Syndrome · United States | 4 | Completed | Sanofi | 216 | |
| NCT00249873Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Mar 2009 | 7,554 |
| NCT00243178Atrial Fibrillation · United States, Australia, Austria and more | 3 | Terminated | Sanofi | Sep 2005 | 6,706 |
| NCT00174759Arterial Occlusive Diseases · Australia, Austria, Belgium and more | 3 | Completed | Sanofi | 1,460 | |
| NCT00115375Heart Defects, Congenital · United States, Belgium, Canada and more | 2 | Completed | Sanofi | 92 | |
| NCT00050817Arteriosclerosis · United States, Argentina, Australia and more | 3 | Completed | Sanofi | 15,603 |
How it is read
Names in the registry
- “Clopidogrel”, 41 entries
- “clopidogrel”, 11 entries
- “clopidogrel (SR25990C)”, 4 entries
- “Clopidogrel (SR25990)”, 3 entries
- “clopidogrel (SR25990)”, 3 entries
Conditions, from the studies’ own filings
- Coronary Artery Disease, 5 studies
- Cardiovascular Diseases, 4 studies
- Acute Coronary Syndrome, 3 studies
- Heart Defects, Congenital, 3 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.